Follow-up study for adults starting GMA for Crohn’s or colitis
Part of Digestive system clinical trials.
This study follows adults with inflammatory bowel disease (Crohn’s disease or ulcerative colitis) after their doctor starts a treatment called GMA. It mainly looks at safety and how patients do in real-world care, and may help doctors understand how GMA works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of ulcerative colitis or Crohn’s disease.
- Your treating doctor must decide to start you on GMA as part of your care.
- You must be able to understand the study and sign informed consent willingly.
- You must be able to follow the study steps (no major medical or psychological issues that would interfere).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This study checks whether adding an extra, cross-body “transmural” evaluation (looking at inflammation throughout the bowel) improves care for adults with Crohn’s who are starting or receiving biologic (biotherapy) treatment. It uses close follow-up with stool calprotectin (a marker of gut inflammation) to see if this approach helps control inflammation.
This study looks at proteins from your body and gut bacteria to understand Crohn's disease better. You may join if you are about to have your first colonoscopy for suspected Crohn's and have not had any treatment yet.
This study tests a new investigational drug (called LMT503) for the first time in humans, in healthy volunteers. It is a phase 1 trial that will look at how the body processes the drug and its safety, including how it behaves in the blood. The trial involves taking the drug once (single dose) or multiple times over several days, with close monitoring by the research team.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.